Channod Biopharmaceuticals Channod Biopharmaceuticals

0717—6855399
CN

Channod Biopharmaceuticals

1
1

1

1
1

1

4
4

4

Advanced Pharmaceutical Intermediates
 

View related>>

这是描述信息

Material intermediate

 

View related>>

这是描述信息

Scientific research original drug series
 

View related>>

这是描述信息

Hot Products

ABOUT US

A comprehensive high-tech enterprise integrating R&D, production and sales of pharmaceutical raw materials and intermediates

Yichang Shangnuode Biomedical Technology Co., Ltd.

Yichang Shangnuode Biomedical Technology Co., Ltd. was registered and established in September 2018 and is located in the national biomedical incubator (U Valley in the east of the city) in Yichang City, Hubei Province. It is a research and development, production and sales of pharmaceutical raw materials and intermediates. An integrated high-tech enterprise.

Chanold Laboratories

Rigorous and pragmatic work attitude, focus on product development

企业理念

Patented technology

Rigorous and pragmatic work attitude, focus on product development

企业理念

Talent recruitment

Rigorous and pragmatic work attitude, focus on product development

企业理念

NEWS

21 2022-01
Industry news
Cell sub-journal: Reveals enhanced macrophage ability to kill cancer cells
January 21, 2022 /Bio Valley BIOON/---Blocking the inhibitory checkpoint SIRPα-CD47 can promote the phagocytosis of cancer cells by macrophages, which is a promising approach in anticancer therapy. Efficient phagocytosis is strictly dependent on the co-engagement of prophagocytic receptors—Fc receptors (FcR), integrin CD11b or SLAMF7—with ligands on the surface of cancer cells. ​
21 2022-01
Industry news
Endometrial cancer "immune + targeted" therapy! Merck/Eisai Keytruda+Lenvima: Significantly prolong survival!
Keytruda+Lenvima is an "immune + targeted" combination therapy that has been approved to treat 2 different types of cancer: endometrial cancer (EC), renal cell carcinoma (RCC).
21 2022-01
Industry news
New drug for Parkinson's disease (PD)! NE3107 enters phase 2 clinical: showed higher prokinetic activity in combination with levodopa!
NE3107 is an oral, blood-brain barrier-crossing small molecule compound with anti-inflammatory, insulin-sensitizing and ERK-binding properties.
21 2022-01
Industry news
The world's first BCMA CAR-T therapy! Bristol-Myers Squibb's Abecma (ide-cel) approved in Japan: treatment of multiple myeloma!
Abecma is the world's first marketed BCMA-directed CAR-T cell therapy.

服务热线

0717-5484668

手机联系

15827373718 

邮箱

sales@sndswyy.cn

TOP

Home
About Us
Company Profile Culture Environmental Patented Honor
Product
Material intermediate Scientific research original drug series Advanced Pharmaceutical Intermediates
Patented
News
Careers
Talent Concept Recruitment
Contact

Contact us

Contact: Mr. Lu
Tel：0717-6855399   15377615856
QQ：2710885149
E-mail：sales@sndswyy.cn
Add：Building 11, No. 519, Juxiang Road, Wujiagang, Yichang City, Hubei Province

 Copyright   2022 Yichang Shangnuode Biomedical Technology Co., Ltd. All rights reserved SEO label  鄂ICP备2021022125号-1